Development of RI-Labeled Oncotropic Compounds (Report VI)

—Affinity for Tumor of ⁵⁷Co-Bleomycin—

Abstract

⁵⁷Co-BLM has an affinity for tumor. There is little possibility that the affinity for tumor of ⁵⁷Co-BLM is due to vascularity of tumor or any secondary change in the adjacent tissues. The results of our present study suggest the dissimilarity of ⁵⁷Co-BLM to BLM (copper free) in property and, moreover, the lesser toxicity of the former substance. All these results, including data relevant to exposure dose, may be considered to warrant the clinical use of ⁵⁷Co-BLM.